Not finding it? Sign in to also search OpenAlex live.
-
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.2022 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Minke W. Lucas, J. Lijnsvelt, Saskia M. Pulleman, Richard A. Scolyer, Alexander Maxwell Menzies, Alexander C. J. van Akkooi, +13 more
47citations -
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.2024 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management Open access
Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander Maxwell Menzies, Marta López‐Yurda, +14 more
27citations -
Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.2024 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Minke W. Lucas, Reetta Arokoski, Alexander Maxwell Menzies, Saskia M. Pulleman, Robyn P.M. Saw, Winan J. van Houdt, +14 more
2citations -
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol
Brigit van Dijk, Karlijn de Joode, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, M. J. Boers‐Sonderen, +15 more
7citations -
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)
Viktor Grünwald, Jurgen Alt, Mareike Tometten, Mathias Hänel, Philipp Ivanyi, Gunter Schuch, +7 more
0citations -
LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial2024 Annals of Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management Open access
M.W. Lucas, Alexander Maxwell Menzies, Marta López‐Yurda, Richard A. Scolyer, Bart A. van de Wiel, Robyn P.M. Saw, +14 more
14citations -
LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma2025 Annals of Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
M.W. Lucas, Alexander Maxwell Menzies, Petros Dimitriadis, S C M A Wijnen, Marta López‐Yurda, Richard A. Scolyer, +13 more
12citations -
1140TiP Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
Brigit van Dijk, Karlijn de Joode, MJB Aarts, Franchette W.P.J. van den Berkmortel, C.U. Blank, M. J. Boers‐Sonderen, +13 more
0citations -
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
Arnaud Scherpereel, Scott Joseph Antonia, Francesco Grossi, Dariusz Mirosław Kowalski, Gérard Zalcman, Anna K. Nowak, +10 more
31citations -
Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real‐world matched comparison of overall survival2025 International Journal of Cancer article Medicine Esophageal Cancer Research and Treatment Open access
Rob H.A. Verhoeven, Steven C. Kuijper, Marije Slingerland, Bas P. L. Wijnhoven, Mark I. van Berge Henegouwen, Peter S.N. van Rossum, +4 more
4citations -
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 7432026 Journal of Clinical Oncology article Medicine Occupational and environmental lung diseases Open access
Arnaud Scherpereel, Paul Baas, Anna K. Nowak, Anne S. Tsao, Nobukazu Fujimoto, Solange Peters, +14 more
8citations -
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Irene L. M. Reijers, Alexander Maxwell Menzies, Alexander C. J. van Akkooi, Judith M. Versluis, N.M.J. Van Den Heuvel, Robyn P.M. Saw, +31 more
378citations -
ISA101 and nivolumab for HPV-16 + cancer: updated clinical efficacy and immune correlates of response2022 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access
Luana Guimarães de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales, Renee L. Chin, Lei Feng, Qi Wang, +12 more
98citations -
Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care2020 Translational Lung Cancer Research article Medicine Cancer Immunotherapy and Biomarkers Open access
Robert D. Schouten, Lucie Egberink, Mirte Muller, Cornedine Jannette de Gooijer, Erik D. van Werkhoven, Michel M. van den Heuvel
11citations -
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma2024 New England Journal of Medicine article Medicine Cutaneous Melanoma Detection and Management Open access
Christian U Blank, Minke W Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander Maxwell Menzies, Marta López‐Yurda, +62 more
538citations